SDC1 and Miyoshi myopathy: In fact, when we mixed CD138+ and CD138- cell populations from MM patients’ bone marrow samples and incubated them with the nanoparticles, we found that the BCMA-BTZ-NPs killed the lowest percentage of non-tumor (CD138-) cells and the highest percentage of MM (CD138 + ) cells (Fig. 2H, I).